News

Honors and Awards November 22, 2021

Four Damon Runyon alumni elected into the National Academy of Medicine

The National Academy of Medicine provides independent, evidence-based scientific advice to address national and global health challenges. Membership is considered to be one of the highest honors in the medical field and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. This year, four Damon Runyon alumni were nominated for membership, bringing the total number of Damon Runyon scientists in the organization to 41.

Honors and Awards October 28, 2021

Damon Runyon Honors William G. Kaelin, Jr., MD, and Kenneth C. Frazier at Annual Breakfast

Damon Runyon was thrilled to hold its Annual Breakfast in person at Cipriani 42nd Street in New York on October 20. The event raised over $1 million to support promising early-career scientists pursuing innovative strategies to prevent, diagnose, and treat all forms of cancer.

Honors and Awards October 28, 2021

Damon Runyon Honors William G. Kaelin, Jr., MD, and Kenneth C. Frazier at Annual Breakfast

Damon Runyon was thrilled to hold its Annual Breakfast in person at Cipriani 42nd Street in New York on October 20. The event raised over $1 million to support promising early-career scientists pursuing innovative strategies to prevent, diagnose, and treat all forms of cancer.

Honors and Awards October 21, 2021

Damon Runyon mourns loss of beloved Board Member, David M. Livingston, MD

It is with great sadness that we share the news that one of our longtime Board Members, David M. Livingston, MD, passed away unexpectedly on Sunday, October 17.

Honors and Awards October 5, 2021

Damon Runyon scientists awarded Nobel Prize in Physiology or Medicine

Damon Runyon is delighted to announce that the 2021 Nobel Prize in Physiology or Medicine has been awarded jointly to David Julius, PhD, and Ardem Patapoutian, PhD, "for their discoveries of receptors for temperature and touch."

Honors and Awards August 11, 2021

It Takes a Village: Bringing a New Drug to Patients with Breast Cancer

For Vassiliki Karantza, MD, PhD, the past seven years have been a whirlwind. Since starting her first job in the pharmaceutical industry in 2014, the former Damon Runyon Clinical Investigator has overseen the development of a new drug for breast cancer from early clinical trials to approval by the Food and Drug Administration. As of March 2021, the drug, pembrolizumab (Keytruda), is FDA-approved for the treatment of metastatic triple-negative breast cancer (TNBC), which accounts for 10-15% of breast cancer diagnoses. It is a remarkable achievement, especially considering that the company’s breast cancer program did not yet exist when Dr. Karantza arrived.

Honors and Awards August 5, 2021

Damon Runyon Cancer Research Foundation awards Fellowships to 17 exceptional early-career scientists

Grants totaling nearly $4 million give early-career investigators independence to pursue brave and bold cancer research.

Honors and Awards July 29, 2021

Damon Runyon welcomes new Board Member

Damon Runyon is pleased to announce that Meghan Raveis was elected to the Board of Directors in June.

Honors and Awards July 16, 2021

Damon Runyon Cancer Research Foundation awards $4.8 million to rising investigators

Damon Runyon Cancer Research Foundation has announced the 2021 recipients of the Damon Runyon Clinical Investigator award—six outstanding early career physician-scientists working to develop new cancer therapies under the mentorship of the nation's leading scientists and clinicians.

Honors and Awards June 29, 2021

“A Silent Cure”: Going Beyond Biology to Understand Cancer Prevention

Note: This is an extended version of an interview published in the Spring 2021 issue of our print newsletter, Momentum.

Former Damon Runyon Clinical Investigator Li Li, MD, PhD, MPH has been appointed to the U.S. Preventive Services Task Force, a sixteen-member panel of experts that makes recommendations for screenings and other preventive healthcare measures for the entire U.S. population. He spoke with us about the role of prevention in the continuum of cancer care.

Damon Runyon News